19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 1
OA-01-TB preventive therapy in HIV
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-01-TB preventive therapy in HIV
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-01-500-21-Isoniazid preventive therapy interruptions and TB among people living with HIV in the Democratic Republic of the Congo Isoniazid preventive therapy (IPT) is a critical prevention intervention for people living with HIV (PLHIV) in high tuberculosis (TB) burden settings, such as the Democratic Republic of the Congo. However, isoniazid shortages result in frequent IPT interruptions among PLHIV. We analysed data from the integrated HIV/AIDS project in Haut Katangato to understand potential impact of isoniazid interruptions.

Ibou Thior

11:13 - 11:21: OA-01-501-21-The effect of antenatal isoniazid preventive therapy on birth outcomes in western Kenya Isoniazid preventive therapy (IPT) reduces risk for tuberculosis (TB) disease in people living with HIV and AIDS. However, there is conflicting data on maternal IPT safety in pregnancy related to birth outcomes. We evaluated programmatic data in Kisumu, Kenya, to assess birth outcomes among women with, and without, antenatal IPT exposure.

Elizabeth Quincer

11:21 - 11:29: OA-01-502-21-Birth outcomes of pregnant women exposed to isoniazid preventive therapy Tuberculosis (TB) is associated with increased risk of death and morbidity among HIV-positive pregnant women. Antiretroviral therapy and isoniazid preventive therapy can reduce mortality rates among HIV-positive pregnant women in high burden settings. Findings suggest that IPT can be safely used during the second and third trimester of pregnancy.

Sikhethiwe Masuku

11:29 - 11:37: OA-01-503-21-Isoniazid preventive therapy added to ART to prevent TB disease: an individual participant data meta-analysis Isoniazid preventive therapy (IPT) prevents tuberculosis (TB) in people living with HIV (PLHIV). We conducted an individual, participant data meta-analysis of randomised controlled trials to estimate the effect of IPT with antiretroviral therapy to prevent TB and death among PLHIV across subgroups by sex, CD4 count and immune sensitisation to TB.

Jennifer Ross

11:37 - 11:45: OA-01-504-21-Impact of TB preventive therapy on TB incidence among persons living with HIV receiving antiretroviral therapy in Nairobi, Kenya (2015–2019) People living with HIV (PLHIV) have a high tuberculosis (TB) comorbidity rate. TB preventive treatment (TPT) significantly reduces TB incidence among PLHIV. We analysed five-year, HIV programme data to determine TB incidence and relative risk among PLHIV who did or did not receive TPT.

Herman Weyenga

11:45 - 11:53: OA-01-505-21-Comparing IsoScreen results and self-reported isoniazid preventative therapy adherence among HIV-positive pregnant women in South Africa This abstract describes a comparison of self-reported, isoniazid preventative therapy adherence (IPT) and adherence as measured by the IsoScreen urine test, among HIV-positive women who initiated IPT during the iThamby study, at six sites in three provinces of South Africa.  The IsoScreen test was conducted across multiple study visits.

Tebogo Sole

11:53 - 12:01: OA-01-506-21-Suboptimal adherence to isoniazid preventive therapy using urine biomarker assessment in children living with HIV: association with viral suppression and age Children living with HIV (CLHIV) are more susceptible to tuberculosis (TB) infection and disease. With optimal adherence, isoniazid (INH) preventive therapy (IPT) reduces the risk of TB by 60%. We assessed adherence to IPT in a prospective cohort of 100 CLHIV using caregiver or child self-report pill counts and urine INH biomarkers.

Dickens Onyango

12:01 - 12:12: Q&A


Loading...
Channel 6
SP-09-Ending TB in vulnerable populations through operational research, capacity building and evidence-informed decision making in Eastern Europe and Central Asia (Find-Treat-All).
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-09-Ending TB in vulnerable populations through operational research, capacity building and evidence-informed decision making in Eastern Europe and Central Asia (Find-Treat-All).
*Please scroll down for more information*
The objective is to present new evidence on optimised case finding, use of digital technology for TB diagnosis and care, and adjunctive interventions in complex cases for key populations in Eastern Europe and Central Asia (EECA). The evidence was generated from EECA researchers under the Structured Operational Research and Training Initiative (SORT IT), which is a global partnership coordinated by the TDR, The Special Programme for Research and Training in Tropical Diseases. The specific SORT IT programme that led to this symposium was implemented by Tuberculosis Research and Prevention Center, Armenia, the Alliance for Public Health, Ukraine, The Union and TDR.

15:00 - 15:05: Introduction

15:05 - 15:15: Breaking the one size fits all paradigm: introduction of optimised case finding of TB among key populations in UkraineMissed tuberculosis (TB) cases are disproportionally concentrated among vulnerable populations that often cannot access health systems. These include socially marginalised individuals (people who inject drugs, displaced, homeless, Roma and former prisoners). Based on experience from an optimised case finding (OCF) strategy, which has been effective in HIV detection among key populations, the Alliance for Public Health in Ukraine has adapted a similar strategy for active TB case finding among vulnerable groups. The OCF strategy empowers index TB cases to refer up to eight close contacts within their social network for TB investigations, in contrast to the usual contact tracing strategy limited to household contacts. Study sites were TB clinics in four regions of Ukraine. Four thousand eight hundred contacts of 600 index TB patients, registered between July 2018 and March 2020, were assessed with respect to numbers of TB contacts referred for investigations, the numbers diagnosed and treated for TB, and the numbers needed to screen.
Liliia Masyuk
Olga Denisiuk

15:15 - 15:25: Scale-up and impact of an electronic medical record system (Open MRS) and GxAlert on diagnosis of TB and linkage to treatment in TajikistanThe advent of the automated Xpert MTB/RIF assay has so far failed to speed up time between diagnosis and treatment of tuberculosis (TB), mainly because of the need for personnel and paper-based interfaces to link results with TB registers. GxAlert is an electronic data monitoring system that automatically connects Xpert instruments to the network and mobile channels to communicate assay results. This should lead to patients being diagnosed and initiated on treatment more quickly. Tajikistan started scaling up GeneXpert instruments in 2014. From 2017 these instruments were connected to GxAlert. During this period, the country scaled-up a new Open MRS medical information system allowing more reliable recording and reporting of TB control efforts. This study presents the scale-up and national coverage of GeneXpert / GxAlert and Open MRS in Tajikistan, between 2014 and 2019, and the impact of this on TB diagnosis and timely linkages between diagnosis and treatment.
Shodmon Khushvakhtov

15:25 - 15:35: Outcomes of video observed TB treatment for drug-susceptible TB in the Republic of MoldovaAsynchronous video observed treatment (aVOT) has been proposed as an alternative method of ensuring medication adherence in tuberculosis (TB) patients, compared with directly observed therapy (DOT). The current study used 2016-2017 secondary data from the randomised clinical trial (RCT) piloted aVOT strategy, in Chisinau, and data from the national TB register. From 647 TB patients included in the study, 169 were from the RCT group (83 – in aVOT and 86 – in DOT) and 478 – DOT in practical conditions (control group). Based on the suggestions of the parent study aVOT may be an acceptable approach to treatment monitoring. Our supplementary results show that aVOT was superior to DOT in terms of treatment outcomes as well; aVOT was associated with short- and long-term TB treatment favourable outcomes. aVOT, as a new patient-centred approach improving treatment adherence and outcomes, might be recommended as an alternative to DOT strategy in the Republic of Moldova.
Svetlana Doltu

15:35 - 15:45: People who inject drugs in Ukraine: comparative analysis of TB treatment outcomes in relation to opioid substitution therapyPeople who use injectable drugs (PWID), who are often socially marginalised and have limited access to health services, are at high risk of being infected with Mycobacterium tuberculosis and developing tuberculosis (TB). Many PWID are also infected with HIV and hepatitis C. Opioid substitution therapy (OST – using methadone or buprenorphine) is one of the pillars of harm reduction strategies for PWID and should be an integral part of TB care. In Ukraine, the Alliance for Public Health coordinates TB and HIV prevention and care services for PWID and has integrated a model of 'OST with TB care at the same facility'. Between July 2017 and July 2019, there were 200 PWID diagnosed with TB in five large regions of Ukraine. The current study documented numbers on OST, socio-demographic and clinical characteristics of those on and off OST and treatment outcomes in relation to OST, HIV status and hepatitis C.
Tetiana Fomenko

15:45 - 15:55: The effect of psychotherapy/psychiatric support for alcohol use disorder for multidrug-resistant TB in Zhytomyr, UkraineUkraine is among the high burden countries for multidrug/rifampicin-resistant tuberculosis (MDR-TB/RR-TB). The country ranks in the top ten for years lost due to disability and premature mortality as a result of alcohol abuse, and TB control efforts are often adversely affected by alcohol use disorder (AUD). Mental health interventions can be effective in reducing alcohol use and together with psychosocial support, these may improve patients’ adherence to TB treatment and result in more favorable TB treatment outcomes. Of 73 patients with RR-TB in Zhytomyr region, Ukraine, 33 were screened positive for AUD and eligible for mental health interventions: 22 received this support and 11 declined. This study compared the two groups with respect to socio-demographic and clinical characteristics, measures of depression, adherence to TB medications and interim/final TB treatment outcomes. The study also assessed why some patients declined to be helped.
Vitalii Plokhykh

15:55 - 16:20: Q&A session

Loading...
Channel 4
SP-12-Scale-up of joint action on diabetes and TB: lessons from the field
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-12-Scale-up of joint action on diabetes and TB: lessons from the field
*Please scroll down for more information*
Addressing comorbidities is a core component of patient-centred care within the End TB Strategy. Diabetes is associated with a two to three-fold risk of TB. TB can temporarily cause impaired glucose tolerance and a person with TB is significantly more at risk of dying or relapsing if they also have diabetes - all important reasons for collaborative action as outlined in The Union and World Health Organization 2011 Collaborative Framework for Care and Control of TB and Diabetes. This symposium will present evidence on the global uptake of collaborative action on TB and diabetes and share barriers, enablers, plans and opportunities for scale-up.

16:30 - 16:35: Introduction

16:35 - 16:45: Global status on uptake of the Union/World Health Organization Collaborative Framework for the Management of Tuberculosis and DiabetesThe Union/World Health Organization (WHO) Collaborative Framework for the Management of Tuberculosis and Diabetes was published in 2011. While we have seen impressive scale-up of collaborative action on HIV-associated tuberculosis (TB) globally during this period, uptake and scale-up of collaborative TB and diabetes activities appears to have been limited and difficult to gauge. This presentation will introduce the symposium and provide an overview of findings from a policy review conducted by WHO to assess uptake by high burden TB countries of the collaborative framework for the management of tuberculosis and diabetes and outline plans to promote further scale-up.
Annabel Baddeley

16:45 - 16:55: Addressing comorbidities as part of high impact TB interventions in Global Fund funding requests and grantsThe presentation will share opportunities from the Global Fund to address comorbidity as one of the high impact interventions – this includes the Global Fund strategy and policy on supporting comorbidity, integrated services and promotion of innovations. Further opportunities are available through catalytic funding to support innovative interventions to find missing people with tuberculosis/drug-resistant tuberculosis (TB), including among high risk groups such as people with diabetes. Additional resources to address TB and comorbidity could be leveraged through existing country grants (savings and reprogramming), portfolio optimisation and new grants.
Mohammed Yassin

16:55 - 17:05: Challenges, enablers and plans for scaling up integrated action on TB and diabetes: lessons from PakistanThe dual burden of diabetes and tuberculosis (TB) is a serious and growing challenge for the poorly resourced health system of Pakistan, which ranks 5th among the high TB burden countries. The number of diabetics are estimated to rise to 13.9 million by 2020 in Pakistan, increasing country ranking to 4th in the world. This presentation will give an overview of studies that have been conducted to pilot bi-directional screening for diabetes in TB clinics and for TB in diabetes clinics. It will also discuss the challenges and barriers to integration at all levels of the health system and how the country plans to ensure integrated and structured bi-directional screening, referral, case management and follow-up is scaled up from 2020-2023.
Aurangzaib Quadir Baloch

17:05 - 17:15: Experience of initiating TB preventive treatment among people with diabetes in BrazilThe national tuberculosis (TB) programme of Brazil has recently been introducing a policy on TB prevention among people with diabetes. This presentation will give an overview of the epidemiology of TB and diabetes in Brazil, common aspects and areas for synergy between the two programmes, Brazil’s experience of introducing programmatic management of latent TB infection as well as preliminary results of TB preventive treatment in people affected by diabetes.
Denise Arakaki-Sanchez

17:15 - 17:25: Introducing diabetes into TB-HIV collaboration: opportunities and plans for addressing multimorbidity in ZimbabweZimbabwe is one of the high tuberculosis (TB) burden countries with more than half of people with TB co-infected with HIV. In 2017, the prevalence of diabetes among adults in Zimbabwe is estimated to be 1.8% and over 75.0% of those with diabetes had never been diagnosed. This presentation will give an overview of the epidemiological background and the steps taken to assess feasibility of implementation and to scale-up collaborative action on TB and diabetes in Zimbabwe.  It will further discuss the challenges, enablers, opportunities and plans for national scale-up of integrated TB, diabetes and HIV care.
Charles Sandy

17:25 - 17:50: Q&A session

Loading...
E-posters
EP11-TB: HIV and diabetes comorbidities
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP11-TB: HIV and diabetes comorbidities
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP11-197-22-Implementation of a mHealth strategy to increase linkage to and engagement in HIV care among people with TB and substance use in Irkutsk, SiberiaWe implemented a mobile health intervention designed to improve linkage and engagement in care for a tuberculosis/HIV co-infected, substance-using population in Irkutsk, Siberia. We evaluated the impact of this intervention, called MOCT (Russian for ‘bridge’), on various patient adherence measures as well as clinical outcomes over six months.
Jacqueline Hodges

EP11-198-22-Concomitant hepatitis B or C infection in patients with TB in the Netherlands: results of screening specific risk groupsThe Dutch Thoracic Society recommends screening specific risk groups of tuberculosis (TB) patients for hepatitis B and C. Data on this policy has been registered in the national TB register since 2019. Results show that this policy may contribute to elimination strategies set for these diseases in the Netherlands.
Jossy van den Boogaard

EP11-199-22-Impact of universal TB screening (TB-Surge) on HIV case finding in selected facilities. Lessons from the TB-Surge intervention in Akwa Ibom State, NigeriaUniversal tuberculosis (TB) screening - TB-Surge - was implemented to find missing TB cases in health facilities in AkwaIbom, a Nigerian state with high TB-HIV burden. Based on World Health Organization recommendation, HIV testing was offered to patients with presumptive TB. Universal TB screening can contribute significantly to early HIV diagnosis and commencement of antiretroviral theory (ART). 
Chukwuemeka Austin Ihesie

EP11-200-22-An assessment of free radical oxidation of small intestine enterocyte proteins in HIV-TB co-infectionThe article is devoted to the study of free radical processes in the mucous membrane of patients with HIV-TB co-infection. It is known that these processes are intensified under conditions of hypoxia, including cytotoxic origin caused by the inflammatory response in the lung tissue.
Liliia Todoriko

EP11-201-22-Monocyte and lymphocyte ratio as a predictor of TB among people living with HIV after antiretroviral therapy initiationIt is a challenge to diagnose tuberculosis (TB) among people living with HIV (PLWH) due to many of them having atypical presentation. We have demonstrated a simple tool that can help us predict TB incidence using monocytes to lymphocytes ratio (MLR) among HIV-infected people on antiretroviral therapy (ART).
Sivaporn Gatechompol

EP11-202-22-Comorbidities in Filipino people with active-TB disease: baseline data from the Starting Anti-TB Treatment (St-ATT) cohortFilipino data on the prevalence and patterns of comorbidities of malnutrition, diabetes, hypertension and anaemia are scarce. Malnutrition (BMI <17.0 kg/m2) was a common comorbidity (23.1%) followed by diabetes (22.7%), hypertension (14.8%), then anaemia (13.4%). Having >=1 comorbidities was more common in those with drug-resistant TB than those with drug-sensitive TB (61.8% vs 54.6%, p=0.05).
Shuichi Jack Suzuki

EP11-203-22-Prevalence of disseminated TB in HIV-infected persons admitted with sepsis at a tertiary hospital in western KenyaDiagnosis of disseminated tuberculosis (TB) in Persons Living with Human Immunodeficiency Virus (PLHIV) has been a challenge especially in resource-limited settings. The World Health Organization recommends lateral flow lipoarabinomannan antigen assay (LF-LAM) to aid in the diagnosis of active TB in PLHIV. However, its uptake in Kenya is still wanting.
Caroline Gituku

EP11-204-22-Is TB a major comorbidity in adolescent girls and young women living with HIV? A case in Turkana and Homa Bay Counties, KenyaWe documented tuberculosis (TB) testing, diagnosis, treatment initiation and outcomes of adolescent girls and young women (AGYW). AGYW received a comprehensive intervention including HIV testing, antiretroviral therapy (ART) initiation and treatment monitoring as well as increased access to GeneXpert MTB/RIF testing and alcohol acid fast bacilli, plus treatment of drug-sensitive TB with fixed dose combination.

Phelix Mboya

EP11-205-22-Is it necessary to screen for TB in diabetes patients and how to do it? An endocrinologist-based questionnaire survey in Hunan Province, ChinaIs it necessary to screen for tuberculosis (TB) in diabetes patients and how to do it? Let's see what the endocrinologists think and how they do it from an endocrinologist-based questionnaire survey in Hunan Province of China.
Chengli Bei

EP11-206-22-Prevalence of malarial and HIV co-infection among TB presumptive and asymptomatic children aged <5 years in Western KenyaWhile the intersection between HIV and tuberculosis (TB) is well documented, despite the high burden globally of TB and malaria among children, co-infection data is lacking. We studied the prevalence of malaria and HIV co-infection among Kenyan children aged <5 years with presumptive TB compared to asymptomatic controls.
Mark Fajans

EP11-207-22-Incidence of hypokalemia among drug-resistant TB patients receiving delamanid-containing regimen in LesothoA delamanid-containing regimen is commonly used in Lesotho even though it belongs to group C. This is mainly due to its safety profile as well as absence of drug-drug interaction with certain antiretroviral therapy (ART) and, as such, we investigate the incidence of hypokalemia in drug-resistant tuberculosis patients receiving a delamanid-containing regimen.
Lawrence Oyewusi

Loading...
Channel 3
SP-23-Preventing TB in people with diabetes mellitus: where are we now and where are we going?
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-23-Preventing TB in people with diabetes mellitus: where are we now and where are we going?
*Please scroll down for more information*
Diabetes mellitus (DM) increases susceptibility to tuberculosis (TB) infection and the risk of progression from latent infection to active disease. There is evidence that better DM control lowers the risk of TB and strong evidence that preventive therapy reduces the risk of TB in persons with latent TB infection. This symposium will bring together researchers and health professionals to discuss the risk of TB in persons with DM and their close contacts, as well as how to minimise the risk of progression from infection to active disease.  This approach is patient-centred and supports universal health coverage for TB care and achievement of the END TB targets.

16:30 - 16:35: Introduction

16:35 - 16:45: Risk of TB infection in healthcare workers in relation to blood glucose levels and vitamin D statusThe association between diabetes mellitus (DM) and tuberculosis (TB) has been known for many years but studies in the last 15 years highlighted that DM increases the risk of  TB and that patients with dual disease have worse TB treatment outcomes compared with those who have just TB alone. This was a cross-sectional study which sought to understand whether the association between vitamin D and TB risk is modified by fasting blood glucose (FBG) among adult healthcare professionals working in TB hospitals of Mongolia. Adult healthcare workers (doctors, nurses, laboratory staffs, etc) who work in the chosen sites will be recruited and assessed for TB infection using the QuantiFERON-TB Gold Plus (QFT-Plus) assay. Participants will undergo assessment of serum 25-hydroxyvitamin D (25(OH)D), FBG, and lifestyle characteristics.
Ganmaa Davaasambuu

16:45 - 16:55: Recurrence of TB in relation to blood glucose levels and vitamin D status in ChinaWe are following a cohort of 306 tuberculosis (TB) patients who were registered in six clinics and hospitals in Jilin, China, since 2015. Demographic information, TB characters, smoking status, blood glucose and vitamin D level was collected at baseline. TB recurrence information was collected after completion of their anti-TB treatment. Of the 306 patients, eight died during treatment and nine did not remain TB disease free for at least six months since end of the initial treatment. Therefore, 289 patients were qualified to be included in this study. There were 60 people who had at least one TB recurrence during the follow up years. Accumulate risk of recurrence was 20.76% (95% CI, 16.23-25.90%). In the multivariate analysis, risk of recurrence was strongly associated with being over 60 years (P=0.007), re-treatment (P<0.001), with treatment interruption (P=0.002) and smoking (P=0.036); but not significantly associated with their baseline diabetes status and vitamin D levels.
Yan Lin

16:55 - 17:05: Rifapentine-based short-course preventive therapy for diabetes mellitus patients with latent TB infectionBeginning in 2018, a pilot project for screening and treating latent TB infection (LTBI) in TB high-risk populations was launched by Taiwan CDC. In Taichung and Kaohsiung cities, people with poorly controlled diabetes mellitus (DM), defined as HbA1c ≥ 9% within one year, were chosen as the target population for intervention. Between April 2018 and August 2019, a total of 833 subjects were screened by DM specialists and 779 (93.5%) received LTBI testing by QuantiFERON, with a positive result in 200 (25.7%). After being evaluated by pulmonologists, two had active pulmonary TB and 49 declined preventive therapy. In the remaining 149 (female: 63), mean age was 65.2±8.9 and BMI 26.5±3.8. Of them, 45 and 104 received 9H and 3HP regimen, with 38 (84%) and 88 (85%) completing treatment, respectively. In the 3HP group, 7 (7%) suffered from systemic drug reactions. This pilot project demonstrates LTBI policy can be efficiently implemented under a collaborative framework.
Jann-Yuan Wang

17:05 - 17:15: Progression from latent TB infection to active TB disease and effectiveness of isoniazid chemoprophylaxis in persons living with diabetes: an individual participant meta-analysisGlobally, hundreds of millions of people are living with diabetes (PLWD) and are at increased risk of developing tuberculosis (TB). Drawing upon a multicohort collaboration of research groups, we aimed to explore two questions: i) is the increased risk of TB among PLWD predominantly due to increased risk of infection or disease progression? and ii) how effective is isoniazid in the prevention of TB among PLWD with Mycobacterium tuberculosis infection? The results of this work will be presented in this session showing that the increased risk of developing tuberculosis is due to an elevated risk of progression from M. tuberculosis infection to disease and that isoniazid preventive therapy is highly effective in preventing TB among PLWD. Taken together, these findings suggest that PLWD should be prioritised for preventive therapy.

Leonardo Martinez

17:15 - 17:25: Prevention of TB in diabetes (PROTID): a phase 3 randomised trialPROTID (www.protid-africa.com) is the first randomised controlled trial (RCT) globally to examine tuberculosis (TB) preventive treatment among people with diabetes mellitus (DM). (n=3000), comparing 3HP preventive therapy and placebo, with incident TB disease over two years as the primary endpoint. In parallel with the RCT, a cohort of 1000 people with DM, but without evidence of latent TB infection (LTBI) will be followed to confirm whether TB incidence in this group is indeed too low to warrant preventive treatment. PROTID will also evaluate optimal ways to screen people with DM for LTBI and TB; address gaps in prevention and therapeutic management of combined TB and DM; and estimate the population impact and cost-effectiveness of LTBI treatment in people living with DM on TB incidence and transmission.
Reinout van Crevel

17:25 - 17:50: Q&A session

Loading...
Channel 6
OA-24-TB and diabetes
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-24-TB and diabetes
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-24-647-23-High proportion of transient hyperglycemia at TB diagnosis among people living with, and without, HIV in South Africa In a prospective cohort study of culture-confirmed, drug-susceptible tuberculosis (TB) patients in South Africa, we evaluated hyperglycemia before, and after, TB treatment. We assessed whether HIV status was associated with differences in resolution of hyperglycemia after completion of TB treatment.

Yuri van der Heijden

11:13 - 11:21: OA-24-650-23-Optimising diagnosis of diabetes mellitus among TB patients: preliminary findings from a multicentre study in Tanzania Active tuberculosis (TB) has a three-fold increase in populations with diabetes mellitus (DM) with overlapping clinical presentations to compromise clinical outcomes.  A study was conducted to implement an algorithm for DM screening in TB patients for early intervention of DM related complications. 

Kenneth Byashalira

11:21 - 11:29: OA-24-652-23-Prevalence of diabetes mellitus among people tested for TB in urban Uganda The increase in type 2 diabetes mellitus in sub-Saharan Africa where tuberculosis (TB) is also endemic has raised interest in diabetes as a risk factor for TB. We estimated the prevalence of diabetes using hemoglobin A1c among people tested for TB in urban Uganda.

Kamoga Caleb Erisa

11:29 - 11:37: OA-24-653-23-Screening hospitalised patients with diabetes mellitus for TB in rural South Africa This study describes the yield of systematic tuberculosis (TB) screening in hospitalised diabetic patients in two hospitals in rural South Africa where the burden of both diseases is high. The yield in different study sub-groups is described and the incremental yield of different diagnostic methods is shown.

Abera Balcha Bulti

11:37 - 11:45: OA-24-654-23-Performance of random plasma glucose compared to glycated hemoglobin in screening for diabetes in Filipino persons with TB This research assessed the performance of the use of random plasma glucose (RPG) and two-step RPG/HbA1c ≥6.5% to screen diabetic patients (HbA1c ≥6.5%) with tuberculosis in the Philippines. The sensitivity/specificity of RPG 200mg/dL was 38%/100%. Using two-step RPG≥110mg/dL as a first screen, then HbA1c≥6.5%, would have missed 25/100 diabetic cases.

Shuichi Jack Suzuki

11:45 - 12:20: Q&A


Loading...
Channel 2
OA-37-TB and HIV potpourri
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-37-TB and HIV potpourri
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-37-728-24-Depression and its associated factors in persons with multidrug-resistant TB in Myanmar Depression is identified as an important potential comorbidity in persons with tuberculosis (TB), yet data in many settings are scarce. The present study aimed to estimate the prevalence and risk factors of depression in persons with multidrug-resistant TB in Yangon, Myanmar. Relatively high prevalence of depression has been identified in this study.

Phyo Theingi

12:43 - 12:51: OA-37-729-24-Enteropathogens negatively impact antimycobacterial drug pharmacokinetics in children from rural Tanzania Malnourished children undergoing tuberculosis (TB) treatment in rural Tanzania had poor attainment of antimycobacterial pharmacokinetic targets. Overall enteropathogen-burden and bacterial enteropathogen- burden was identified as a risk factor for sub-target rifampin, isoniazid, and ethambutol serum concentrations.

Daniel Van Aartsen

12:51 - 12:59: OA-37-730-24-Finding the missing cases 0ne-by-two: testing contacts of people with presumptive TB to close TB and HIV case finding gaps in the Democratic Republic of Congo Community outreach efforts to identify missing cases are critical to achieving tuberculosis (TB) and HIV epidemic control goals. The United States Agency for International Development-funded integrated HIV/AIDS project in Haut Katanga (IHAP-HK) piloted the one-by-two approach, which was successful in earlier diagnosis of people with TB or HIV who may otherwise have been missed or diagnosed later through usual tracing efforts.  

Charlie Banzakadilo

12:59 - 13:07: OA-37-732-24-Determining the prevalence of TB in emergency departments in the Eastern Cape region of South Africa and the utility of the WHO TB screening tool This study aims to determine the prevalence of tuberculosis (TB) in emergency departments in South Africa and the effectiveness of the World Health Organization (WHO) TB screening tool. While the WHO screening guidelines identify some TB-positive patients, the inclusion of additional criteria could increase the utility of this tool.

Jacob Roberts

13:07 - 13:15: OA-37-733-24-An in vitro intracellular Mycobacterium tuberculosis and HIV-1 co-infection model suitable for imaging-based platforms Mycobacterium tuberculosis (Mtb) and HIV-1 are hazard group 3 pathogens, as such they are worked with and stored in containment level 3 laboratories. The aim of this work was to develop a safe methodology to co-infect macrophage cells with Mtb and HIV-1 to monitor pathogen interactions for drug screening purposes.

Samantha Donnellan

13:15 - 13:23: OA-37-734-24-Impact of integrating mental health services within existing TB treatment facilities Patients with tuberculosis (TB) are at a higher risk of developing depression and anxiety, which can adversely impact treatment adherence. This study evaluates whether the integration of mental health services within TB programmes can help to alleviate symptoms of depression and anxiety and improve TB treatment completion among drug-susceptible TB patients.

Aneeta Pasha

13:23 - 13:50: Q&A


Loading...
Processing. Please wait.
Loading...